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Summary
The natural product lovastatin and its semisynthetic,
more effective derivative, simvastatin, are important
drugs for the treatment of hypercholesterolemia.
Here, we report the biochemical characterization of a
dedicated acyltransferase, LovD, encoded in the lova-
statin biosynthetic pathway. We demonstrate that
LovD has broad substrate specificity towards the
acyl carrier, the acyl substrate, and the decalin acyl
acceptor. LovD can efficiently catalyze the acyl trans-
fer from coenzyme A thioesters or N-acetylcysteamine
(SNAC) thioesters to monacolin J. When a-dimethyl-
butyryl-SNAC was used as the acyl donor, LovD was
able to convert monacolin J and 6-hydroxyl-6-desme-
thylmonacolin J into simvastatin and huvastatin,
respectively. Using the Escherichia coli LovD overex-
pression strain as awhole-cell biocatalyst, preparative
amounts of simvastatin were synthesized in a single
fermentation step. Our results demonstrate LovD
is an attractive enzyme for engineered biosynthesis
of pharmaceutically important cholesterol-lowering
drugs.
Introduction
Lovastatin (Mevacor; 1; Figure 1) is a fungal polyketide
produced byAspergillus terreus [1–4]. It is a pharmaceu-
tically important compound because of its potent inhib-
itory activity toward hydroxymethylglutaryl coenzyme A
(CoA) reductase, the rate-limiting step of cholesterol
biosynthesis. Simvastatin (Zocor, 2) is a semisynthetic
analog of 1 and is more effective in treating hypercholes-
terolemia [5, 6]. Substitution of the a-methylbutyrate
side chain with a-dimethylbutyrate significantly in-
creases the inhibitory properties of 2, while lowering un-
desirable side effects. In 2005, simvastatin was the sec-
ond-best-selling drug in the United States, with annual
sales exceeding $4.5 billion. Other important natural
product-derived statins include pravastatin (5) [7] and
huvastatin (6) [8].
*Correspondence: yitang@ucla.eduBecause of the importance of simvastatin, various
multistep syntheses of 2 starting from 1 have been
described in the patent literature [9–11]. For example, a
widely used process starts with the hydrolysis of the
C8 ester in 1 to yield the triol monacolin J (3), followed
by selective silylation of the C13 alcohol, esterification
of C8 alcohol with dimethylbutyryl chloride, and depro-
tection of C13 alcohol to yield 2 [12]. Enzymatic transfor-
mations using lipases and esterases have been investi-
gated as alternatives to chemical derivation [13, 14].
However, the requirement of regioselective esterification
of the C8 alcohol invariably involves protection of other
reactive alcohol groups in 3, and generally leads to low-
ered overall yield. Therefore, a specific reagent that is
able to selectively acylate C8 of 3 is important for the
efficient synthesis of 2 and additional statin analogs.
Pioneering works by Reeves [15] and Hutchinson and
Vederas [16] have identified the gene cluster for lova-
statin biosynthesis in A. terreus. The biosynthesis of 1
is coordinated by two iterative type I polyketide syn-
thases and numerous accessory enzymes. Nonaketide
3, the immediate biosynthetic precursor of 1, is assem-
bled by the upstream megasynthase LovB [15] (also
known as lovastatin nonaketide synthase), enoylreduc-
tase LovC, and CYP450 oxygenases. The five carbon
unit side chain is synthesized by LovF (also known as
lovastatin diketide synthase) through a single conden-
sation between an acetyl-CoA and a malonyl-CoA. The
condensed diketide undergoes methylation and reduc-
tive tailoring by the individual LovF catalytic domains
to yield an a-S-methylbutyryl thioester covalently at-
tached to the phosphopantetheine arm on the acyl car-
rier protein (ACP) domain of LovF [16]. Encoded in the
gene cluster is a 46 kDa protein, LovD, which was initially
identified as an esterase homolog. LovD was suggested
to catalyze the last step of lovastatin biosynthesis that
regioselectively transacylates the acyl group from
LovF to the C8 hydroxyl group of 3 to yield 1 (Figure 2).
Inactivation of either LovD or LovF in A. terreus led to
accumulation of the precursor 3 [16].
Homologous enzymes to LovD can be found in other
fungal polyketide gene clusters. MlcH in the compactin
biosynthetic pathway is implicated in the catalysis of
the transacylation reaction between 6-desmethylmona-
colin J and an identical acyl substrate [17]. An acyltrans-
ferase in the recently discovered squalestatin pathway
in Phoma sp. C2932 likely catalyzes a similar reaction
between an ACP bound tetraketide thioester and an
aglycone to yield squalestatin [18]. The amino acid se-
quence of LovD resembles type C b-lactamase en-
zymes, which catalyze the hydrolytic inactivation of the
b-lactam class of antibiotics [19, 20]. Alignment of
LovD with the well-characterized Enterobacter cloacae
P99 lactamase [21] shows moderate sequence homol-
ogy, including the potentially conserved nucleophilic ac-
tive site residues Ser76 and other catalytic amino acids,
such as Lys79, Tyr188, and Lys315 [21].
We reason that LovD would be an attractive candidate
for the chemoenzymatic synthesis of lovastatin analogs
if it, indeed, regioselectively acylates the C8 hydroxyl
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1162Figure 1. Lovastatin (1), Simvastatin (2), Monacolin J (3), Pravastatin (5), Huvastatin (6), and 6-Hydroxyl-6-Desmethylmonacolin J (7)position in 3. Three biochemical properties of LovD re-
main unexplored. First, can the transacylation activity
of LovD be confirmed in vitro and be reconstituted in
a heterologous host? Second, does LovD require pro-
tein-protein interactions with specific LovF domains
for catalysis? Previous work by Kennedy and coworkers
suggested LovD-LovF interaction is necessary, al-
though no in vitro characterization was performed [16].
Substitution of acyl-S-LovF with synthetic thioesters
may significantly increase the chemical diversity of the
acyl moieties. Third, what is the substrate specificity of
LovD toward the acyl moiety, the thioester carrier, and
the decalin core? Can LovD directly acylate 3 with a-di-
methybutyrate to yield the pharmaceutically important
2? In this report, we examine these properties of LovD
and demonstrate that LovD displays broad substrate
specificity. We also show that LovD can be a useful bio-
catalyst for the synthesis of 2 and other statin analogs.
Results and Discussion
LovD Regioselectively Acylates Monacolin J
The lovD gene was amplified from A. terreus genomic
DNA by splice-by-overlap extension PCR to delete thetwo introns, and the amplified DNA was inserted into
the pET28a expression vector. Overexpression of solu-
ble,N-terminal 63His fusion LovD was performed using
Escherichia coli strain BL21(DE3)/pAW31 at 18C. Ele-
vated expression temperature resulted in significant
aggregation of LovD into inclusion bodies. Following
overnight expression, soluble LovD was purified using
a single step Nickel-NTA affinity column to near homo-
geneity (Figure 3). The final yield of pure LovD is w40
mg/l.
Due to lack of the cognate substrate a-methylbutyryl-
S-LovF, we directly examined whether an acyl-CoA can
be used as the acyl donor in the transacylation reaction.
The substrate 3 (1 mM) was prepared through the LiOH
hydrolysis of 1 and was added to a reaction mixture con-
taining pure LovD (10 mM) and butyryl-CoA (4 mM),
which is a commercially available acyl-CoA that best
mimics the natural a-methylbutyrate side chain. The
reaction mixture was incubated at room temperature,
extracted with ethyl acetate, and analyzed by HPLC
and LC-MS (Figure 4A).
A single, more hydrophobic compound, with an iden-
tical UV absorbance to that of 1, was formed in the reac-
tion mixture in conjunction with the disappearance of 3Figure 2. Proposed Acyl Transfer Reaction
in A. terreus
The reaction likely follows a ping-pong bi-bi
mechanism. LovD first captures the a-meth-
ylbutyryl acyl group synthesized by the meg-
asynthase LovF, followed by the transacyla-
tion of the C8-hydroxyl moiety of monacolin
J to yield the natural product lovastatin.
Ser76 is the putative active site nucleophile.
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found to be 391 (M + H)+, in accordance with addition of
a butyryl group to 3. The selective esterification of the C8
hydroxyl group of 3 to yield 4 was confirmed by proton
NMR spectroscopy (CDCl3, 500 MHz). The proton NMR
spectrum of 4 (lactonized form) is nearly identical to
that of 1 (see Experimental Procedures), except for the
aliphatic signals of the linear acyl side chain. The diag-
nostic H8 multiplet (assigned using 1H-1H COSY,
Figure 3. Expression and Purification of LovD from E. coli
BL21(DE3)/pAW31
Lane 1, Flow through of whole cell lysate soluble protein over the
Ni-NTA column; lane 2, 10 mM imidazole wash; lane 3, 20 mM
imidazole wash; lane 4, 50 mM imidazole wash; lane 5, 250 mM
imidazole elution 1; lane 6, 250 mM imidazole elution 2; and lane
M, broad range molecular weight marker. The size of the N-63
His-LovD is 48 kDa. Only the protein in lane 5 was concentrated,
buffer exchanged, and used in assays described here.1H-13C HMQC, and 1H-13C HMBC) in 4 is shifted down-
field to d 5.39, compared with d 4.23 observed for the
same proton in 3. This is consistent with the deshielding
effect of the acyloxy substitution at C8. Protons H11 and
H13 of carbons bearing other hydroxyl groups were
shifted from d 4.71 and d 4.38 in 3 to d 4.61 and d 4.37
in 4, respectively.
As shown in Figure 4A (trace a), 87% conversion of 3 to
4 was observed after 10 hr using butyryl-CoA as an acyl
donor. A time-course study revealed an initial turnover
rate (ki; V/Eo) of 0.18 min
21 (Figure 4B). The observed
87% conversion is likely approaching equilibrium, as
evident in Figure 4B. To examine the biochemical nature
of the equilibrium conversion, we assayed whether LovD
also catalyzes the reverse, hydrolysis reaction. Indeed,
when 1 was used as the only substrate in the presence
of LovD, formation of 3 was readily detected with kcat
and Km values of 0.21 6 0.01 min
21 and 0.56 6 0.05
mM, respectively (Figure 4C). An excess of butyryl-
CoA was, therefore, necessary for achieving maximum
conversion of the forward reaction.
To verify the catalytic role of LovD, we constructed
a mutant form of lovD that contained a Ser76-to-Ala76
substitution. Ser76 was identified through sequence
alignment with type C b-lactamase to be the putative,
active site nucleophile. When the LovD S76A mutant
was used in place of the wild-type enzyme, neither for-
mation of 4 (Figure 4A, trace b) nor the hydrolysis of 1
could be detected. The enzymatic synthesis of 4 con-
firms that LovD indeed catalyzes the acyl transfer reac-
tion shown in Figure 2. Furthermore, this result suggests
that direct association between domains of LovF and
LovD is not an absolute requirement for catalytic turn-
over, in contrast to the previously suggested mode of
LovD catalysis [16]. Acyl-S-CoA can substitute forFigure 4. Verification of LovD Activity
(A) HPLC (238 nm) trace showing formation
of 4 by LovD-mediated acyl transfer. Gradi-
ent: 60% B–95% B, 5 min; 95% B, 15 min;
(a) LovD + 3 + butyryl-CoA time course (0,
1, 3, 6, and 10 hr); (b) LovD S76A + 3 + bu-
tyryl-CoA, 10 hr; (c) LovD + butyryl-SNAC,
10 hr; (d) LovD + butyryl-SMTG, 10 hr. Assay
conditions: 1 mM 3, 4 mM butyryl-CoA, 10
mM LovD, 50 mM HEPES, pH 7.9, 25C.
(B) Conversion as a function of time for bu-
tyryl-CoA (open diamonds), butyryl-SNAC
(closed diamonds), and butyryl-SMTG
(closed squares). The apparent kcat values
reported throughout the text are initial turn-
over rates in the linear range.
(C) LovD catalyzed hydrolysis of 1 to 3. The
reaction progress is monitored by HPLC.
kcat: 0.21 6 0.01 min
21; Km: 0.56 6 0.05 mM.
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cantly higher Km due to the loss of potential protein-
protein interactions.
Monacolin J Is a Competitive Inhibitor of LovD
With the HPLC assay shown in Figure 4A established,
we measured the steady-state kinetic parameters of
LovD toward butyryl-CoA and 3 by varying the concen-
trations of both substrates. Each data point shown is the
result of three repeated measurements. The acylation
reaction likely proceeds through a ping-pong mecha-
nism, as shown in Figure 2, in which butyryl-CoA first
binds to the free LovD, followed by dissociation of free
CoA-SH and binding of 3 to effect acyl transfer. The con-
centrations of butyryl-CoA in the assays varied between
1 and 10 mM, while the sensitivity of the HPLC assay lim-
ited the lowest concentration of 3 to 50 mM. The enzyme
concentrations ranged between 0.5 and 5 mM, depend-
ing upon the concentration of 3.
Figure 5A shows the V/Eo of the acylation reaction as
a function of increasing butyryl-CoA concentration. In-
terestingly, within the examined concentration range of
3 (50 mM–2 mM), we observed a marked decrease of
product turnover rate at higher concentrations of 3.
This is indicative of excess substrate inhibition occur-
ring due to binding of 3 to free LovD, forming a LovD-3
complex and blocking entrance of butyryl-CoA. In con-
trast, no substrate inhibition by butyryl-CoA at high con-
centrations was observed (Figure 5A).
Figure 5B shows the Lineweaver-Burk plot of the data
in Figure 5A, and reveals that 3 is a competitive inhibitor
of butyryl-CoA, as expected. From the intercept of the
plot, the kcat of the reaction is estimated to be 0.53 6
0.08 min21. The apparent Km values of butyryl-CoA at
fixed concentrations of 3 were calculated using nonlin-
ear least-squares fitting and are plotted in the inset in
Figure 5B. Linear regression of the plot indicates that
the Km for butyryl-CoA and KI for 3 are 1.59 6 0.15 mM
and 330 6 36 mM, respectively.
LovD Has Broad Substrate Specificity toward the
Acyl Substrate
We assayed the tolerance of LovD toward different acyl
substituents by performing the transacylation assay
with various commercially available acyl-CoAs (Table 1).
All assays were performed with 1 mM 3 to facilitate de-
tection of products, 4 mM acyl-CoA, and 10 mM LovD.
The reaction mixtures were kept at room temperature
for 10 hr and were then extracted and analyzed by
HPLC and LC-MS. With the exceptions of malonyl- and
palmitoyl-CoA, a single, new compound matching the
expected increase in mass as a result of transacylation
was detected in each of the reactions (Table 1). Further-
more, in each case, no product formation could be
detected in the absence of LovD.
Our results clearly indicate that LovD displays prefer-
ence toward medium chain length (C3–C6) acyl groups,
with butyryl-CoA being the optimal alkylacyl-CoA sub-
strate. Both acetyl- and octanoyl-CoA were poor sub-
strates of LovD, with <10% acylation of 3. Surprisingly,
the bulkier benzoyl-CoA was one of the best acyl sub-
strates examined, with nearly 70% conversion of 3 to
the corresponding C8-benzoyl-monacolin J analog (ki =
0.16 min21). Introducing a-b unsaturation significantlydecreased the reaction rate, as seen in the 6% acylation
of 3 in the presence of crotonyl-CoA. Acetoacetyl-CoA
and b-hydroxylbutyryl-CoA were both excellent sub-
strates of LovD, in good agreement with the isolation
of monacolin X [22] and monacolin M [23] from the natu-
ral host, respectively. The side chains of these shunt
products are likely formed due to the derailment of the
LovF reductive tailoring steps, and were subsequently
transferred by the broadly specific LovD.
LovD Accepts Membrane-Permeable Thioesters
To further examine the substrate specificities of LovD
toward alternative acyl carriers, especially those that
are simpler to prepare synthetically, and can penetrate
Figure 5. Kinetic Properties of LovD using Butyryl-CoA as an Acyl
Substrate
(A) Kinetic analysis of LovD catalyzed acylation of 3 in the presence
of butyryl-CoA. Initial turnover rates (V/Eo) as a function of butyryl-
CoA concentration with different concentrations of 3. The lines are
fitted with nonlinear least squares regression to Michaelis-Menten
kinetics. The concentrations of 3 used in these assays were 0.05
mM (closed diamonds), 0.2 mM (open squares), 0.5 mM (closed tri-
angles), and 1 mM (closed circles).
(B) Lineweaver-Burk plot of data shown in Figure 5A reveals that 3
is a competitive inhibitor of the acylation reaction; the kcat is esti-
mated to be w0.53 min21 from the intercept of the lines. Inset:
the apparent Km values of butyryl-CoA increase as the concentra-
tion of 3 is increased. The actual Km of butyryl-CoA and KI of 3
are determined to be 1.59 6 0.15 mM and 330 6 36 mM.
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variants of butyryl-thioesters as substrates of LovD
(Figure 4A and Table 1). N-acetylcysteamine thioesters
(SNAC) have been used extensively as probes and pre-
cursors in studying natural product biochemistry [24,
25]. Methyl-thioglycolate (SMTG) was recently shown to
be a cost-effective substitute for SNAC in the precur-
sor-directed biosynthesis of erythromycin [26]. Figure 4
(traces c and d) shows the conversion of 3 to 4 when
these butyryl-thioesters were used as acyl donors. Both
SNAC and SMTG thioesters substituted for butyryl-CoA
efficiently, with ki values of 0.09 min
21 and 0.23 min21
(Figure 4B), respectively, further highlighting that pro-
tein-protein interactions between LovD and LovF, as
well as the interaction between LovD and the phospho-
pantetheine arm, are not required for acyl transfer. Bu-
tyryl-thioethane and butyryl-thioethanol, however, were
not competent substrates of LovD, and supported only
4% and 1% conversion of 3 to 4, respectively (data not
Table 1. Acyl-Thioesters as Substrates of LovDa
Acyl
Thioester
Substrate
Conversion
(%)b/RT
(min)c
Acyl
Thioester
Substrate
Conversion
(%)/RT
(min)
7/5.1 89/4.6
35/6.0 35/4.2
52/6.8 6/6.5
87/6.8 NR
32/8.7 NR
7/10.6 69/7.6
50/6.8 58/7.6
22/7.6 10/8.5
52/7.8 92/6.8
33/8.7 70/7.6
2/7.5 17/8.5
NR, no reaction; RT, retention time.
a The products of the reactions were verified by LC-MS. Reaction
conditions: 10 mM LovD, 1 mM 3, 4 mM acyl-thioester, 50 mM
HEPES, pH 7.9, 25C, 10 hr.
b Conversion is measured by the percent 3 converted to the corre-
sponding lovastatin analog using HPLC (238 nm).
c HPLC (C18 reverse phase) retention time of the free acid form of
product. The HPLC gradient is the same as described in Figure 4.shown). Similarly, benzoyl-SNAC and benzoyl-SMTG
substituted for benzoyl-CoA efficiently, with ki values of
0.12 min21 and 0.15 min21, respectively (Table 1).
We then synthesized a-S-methylbutyryl-SNAC and
a-dimethylbutyryl-SNAC and assayed for the in vitro
chemoenzymatic synthesis of 1 and 2, respectively.
The results are shown in Figure 6A and Table 1. Authen-
tic samples of 1 and 2were used as references for HPLC
detection (Figure 6A, trace a). The cognate, a-S-methyl-
butyrate side chain was, surprisingly, a poorer substrate
compared with butyryl-, pentanoyl-, and hexanoyl-
SNAC. The initial turnover rate (kiz 0.04 min
21) of 1 syn-
thesis was more than 50% slower than that of LovD
toward butyryl-SNAC under identical conditions. This
suggested that the wild-type LovD has not been opti-
mized for transferring the branched substrate. Addi-
tion of a second methyl substitutent at the a-position
further attenuated the rate of acylation, likely attributed
to the increased steric hindrance of the dimethyl
moiety. Approximately 10% of 3 was converted to 2
when a-dimethylbutyryl-SNAC was used as a substrate
(ki = 0.02 min
21). We were able to reach equilibrium con-
versions >70% when 100 mM LovD and a 10-fold excess
of a-methyl-SNAC or a-dimethyl-SNAC were added to
the in vitro reaction mixture (Figure 6A, traces b and c).
The hydrolysis rate of 2 (kcat/Km = 0.30 min
21 mM21)
by LovD was comparable to that of 1.
LovD Can Accept Alternative Decalin Cores
To test the substrate specificity of LovD toward mona-
colin J variants, we assayed the conversion of tetra-ol
7 to 8, pravastatin (5), and huvastatin (6) (Figure 6B).
Vederas and coworkers have previously shown that,
when 6-desmethyl-monacolin J is fed to an A. terreus
mutant blocked in biosynthesis of 3, compactin can be
readily isolated [27]. This hints that LovD may be tolerant
of substitutions at the C6 position of the decalin core.
The novel compound 6 has recently been shown to
have excellent pharmacological properties as a choles-
terol-lowering compound [8]. Its synthesis from pravas-
tatin is, however, further complicated by the presence of
an additional reactive alcohol at C6. A LovD-mediated
biotransformation that regioselectively acylates 7 to
yield 6 could, therefore, be an attractive route.
To prepare the substrate 7, we utilized the hydrolytic
properties of LovD. When 5 is incubated with LovD un-
der standard assay conditions, 7 can be readily formed.
Using a 10 kDa MWCO spin column to remove LovD
after complete hydrolysis, we were able to recover 7 in
quantitative yield. The comparable rate of hydrolysis of
5 (kcat/Km = 0.21 min
21 mM21) by LovD to that of 1 hints
that the C6 modified decalin core will not attenuate the
rate of the acylation reaction significantly. Indeed,
LovD displays relaxed specificity toward the hydroxyl
substitution at C6 and catalyzed the acylation of 7 with
higher efficiencies. The initial turnover rates for the
synthesis of 8, 5, or 6 using the corresponding acyl-thio-
esters were 0.18, 0.11, and 0.03 min21, respectively. The
retention time of authentic 5 was identical to the enzy-
matically synthesized compound. The mass of the newly
formed compounds were verified by LC-MS. We did not
detect any di-acylated products in the reaction mixture,
further highlighting the exceptional regioselectivity of
LovD toward the C8 hydroxyl group.
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SNAC substrates
(A) HPLC (238 nm) trace showing formation
of 1 and 2 by LovD-mediated acyl transfer.
The gradient is the same as that described
in Figure 4. (a) authentic standards of 1 and
2; (b) 3 + a-S-methylbutyryl-SNAC; (c) 3 +
a-dimethylbutyryl-SNAC. Assay conditions:
1 mM 3, 10 mM acyl-SNAC, 100 mM LovD,
50 mM HEPES, pH 7.9, 25C, 6 hr.
(B) HPLC (238 nm) traces showing formation
of 5 and 6 by LovD-mediated acylation of the
tetra-ol 7. Gradient: 5% B–95% B, 5 min;
95% B, 15 min; (a) authentic standards of 5
and 7; (b) 7 + a-S-methylbutyryl-SNAC; (c)
7 + a-dimethylbutyryl-SNAC. Assay condi-
tions: 1 mM 3, 10 mM acyl-SNAC, 100 mM
LovD, 50 mM HEPES, pH 7.9, 25C, 6 hr.Whole-Cell Biocatalysis with LovD
To demonstrate that LovD can be used for preparative
biosynthesis of lovastatin analogs, we first attempted
to perform the benzylation reaction in vivo using E. coli
as a heterologous host. The BL21(DE3)/pAW31 overex-
pression strain was grown in a shake flask (200 ml) to an
OD600 of 1.0, at which time 1 mM IPTG, 0.8 mM 3, and 4
mM of either benzoyl-SNAC or benzoyl-SMTG were
added to the culture. Expression of LovD and bioconver-
sion was performed at 18C. The culture was extracted
and analyzed for the formation of 8-benzoyl-monacolin
J. When supplemented with benzoyl-SNAC, 84% con-
version of 3 was detected within 20 hr postinduction.
The product was lactonized and purified by a single
silica gel chromatography step. The NMR spectra
confirmed the regioselective benzoylation of the C8
hydroxyl group, as the diagnostic H8 multiplet was
shifted downfield to d 5.61 (see Experimental Proce-
dures). In contrast, only 40% benzoylation was ob-
served for the culture that was supplemented with ben-
zoyl-SMTG, despite the faster in vitro acylation rate to
that of benzoyl-SNAC. We discovered that the low con-
version was due to the rapid degradation of benzoyl-
SMTG by E. coli, and no trace of the precursor could
be detected in the culture medium after 12 hr.
Encouraged by the high yield of conversion using E.
coli as a whole-cell biocatalyst, we performed low cell
density fermentation with a-dimethylbutyryl-SNAC as
a precursor to yield 2 from 3 in a single biosynthetic
step. After 2 days of culturing, we observedw35% con-
version of 3 to 2. The product was purified, and the pro-
ton and carbon NMR spectra were identical to those of
the commercial standard. The lower yield of 2 is consis-
tent with the slower turnover rate observed in vitro,which may be further decreased at lower intracellular
concentration of the SNAC precursor due to diffusion
limitations. Other factors, such as the reversible hydro-
lysis of simvastatin and inactivation of LovD after
prolonged fermentation, may lead to the observed con-
version. We anticipate that the yield can be significantly
improved by several means, such as: (1) using high cell
density fermentation to increase the effective concen-
tration of LovD and optimize fermentation conditions;
and (2) increasing LovD catalytic efficiencies toward
the unnatural precursor by protein engineering.
In conclusion, we have confirmed that LovD catalyzes
the final acyl transfer step during lovastatin biosynthesis
and regiospecifically acylates the C8 hydroxyl group in 3.
LovD displays broad substrate specificity toward the
decalin aglycone, the acyl carrier, and the acyl group.
When supplemented with the unnatural substrate a-
dimethylbutyryl-SNAC, LovD produced the pharmaceu-
tically important simvastatin both in vitro and in vivo.
With optimization of the whole-cell biocatalyst, the one-
step biological synthesis of simvastatin from either 1 or 3
will represent a significant upgrade over the conven-
tional five-step chemical synthesis. In addition, we antic-
ipate that, when an a-dimethylbutyryl-thioester precur-
sor is supplied to a lovF-deficient strain of A. terreus,
the lovastatin biosynthetic pathway can be redirected
to afford 2 directly. We are currently attempting to obtain
the X-ray crystal structure of LovD and use it as a starting
point for enhancing LovD catalytic efficiencies.
Significance
Lovastatin is a natural fungal product that inhibits
the rate-limiting step of cholesterol biosynthesis.
Lovastatin Acyltransferase
1167Understanding the biosynthetic steps of lovastatin
from Aspergillus terreus is, therefore, important for
the engineered biosynthesis of pharmaceutically rele-
vant statin compounds. In this work, we have charac-
terized an acyltransferase (LovD) that catalyzes the
last step of lovastatin biosynthesis. First, we demon-
strate that LovD is an efficient enzyme that transfers
a 2-methylbutyryl acyl group regioselectively to the
C8 hydroxyl of monacolin J, the immediate biosyn-
thetic precursor of lovastatin. The reaction proceeds
via a ping-pong mechanism, and is inhibited by mona-
colin J at moderate substrate concentrations. Second,
we show that LovD has broad substrate specificity to-
ward the acyl carrier, the acyl substrate, and the deca-
lin core of the acyl acceptor. In particular, LovD does
not require protein-protein interactions with themega-
synthase LovF for the acyl transfer activity, and can
accept a variety of acyl groups tethered to mem-
brane-permeable thioesters. Building upon these bio-
chemical insights, we demonstrate that LovD can be
utilized as an effective biocatalyst for the single-step
synthesis of simvastatin, a commercially important
lovastatin analog, both in vitro and in vivo. Our work,
therefore, provides important insights into several
novel features of fungal polyketides biosynthesis,
and can have significant utility in an improved synthe-
sis of simvastatin.
Experimental Procedures
General Procedures
E. coli XL-1 Blue (Stratagene) was used for the manipulation of plas-
mid DNA. E. coli BL21(DE3) (Novagen) was used for protein expres-
sion.A. terreus (ATCC 20542) was cultured for extraction of genomic
DNA. NMR spectra were obtained on Bruker spectrometers (1H, 500
MHz; 13C, 125 MHz; CDCl3) at the NMR facility in the Department of
Chemistry and Biochemistry at UCLA. LC–MS was conducted with
a Finnigan LCQ Deca XP quadrupole ion trap mass spectrometer
by positive electrospray ionization and a Waters 2.1 3 100 mm
C18 reverse-phase column. Samples were separated on a linear gra-
dient of 5%–95% CH3CN (v/v) over 30 min and 95% CH3CN (v/v) for
an additional 30 min in H2O supplemented with 0.05% (v/v) formic
acid at a flow rate of 0.125 ml/min at room temperature.
LovD Cloning, Expression, and Purification
The three exons of lovD were individually amplified from the geno-
mic DNA of A. terreus and fused to yield a continuous open reading
frame by splice-by-overlap extension PCR. The restriction sites
NdeI and HindIII were introduced on the 50 and 30 outside primers,
respectively. The gene cassette was ligated into pET28 (Novagen)
to yield the expression construct pAW31. The E. coli BL21(DE3)
strain transformed with pAW31 was grown in LB medium at 37C
to an OD600 of 0.5, at which time 1 mM IPTG was added to the culture
and expression performed at 18C for 24 hr. Cells were collected by
centrifugation, resuspended in Buffer A (50 mM Tris-HCl, pH 8.0, 2
mM DTT, 2 mM EDTA), and lysed by sonication. Cell debris and in-
soluble proteins were removed by centrifugation (17,000 3 g, 4C,
1 hr). To the cleared lysate, 2 ml of Ni-NTA resin (Qiagen) was added.
LovD was purified using a step gradient of buffer A with increasing
concentration of imidazole. Pure (>95%) LovD proteins were eluted
in buffer Acontaining 250 mM imidazole,buffer exchanged intobuffer
A without imidazole, concentrated, aliquoted, and flash frozen. The
frozen LovD aliquots were for single use only. We observed signifi-
cant decreases in enzyme activity after a single freeze-thaw cycle.
Construction of LovD S76A Mutant
The mutant lovD (Ser76/ Ala76) construct was made by oligo-di-
rected mutagenesis using pAW31 as template and oligonucleotides
50-GACACCCCCTGCCGGCTAGCCGCTGCGACCAAGCTGCT-30 and50-AGCAGCTTGGTCGCAGCGGCTAGCCGGCAGGGGGTGTC-30. The
introduced mutation was verified by DNA sequencing. Expression
and purification of the S76A mutant was performed in identical
fashion as the wild-type enzyme (yield 30 mg/l).
Preparation of 3
Commercially available, lactonized 1 (500 mg) was refluxed in 50 ml 1
M LiOH for 24 hr. After cooling to room temperature, the suspension
was acidified to pH 2.0 and extracted three times with 100 ml ethyl
acetate. The extract was dried, evaporated, and redissolved in
100 ml toluene. A soxhlet apparatus was used to yield the lactonized
form of 3, which was subsequently purified with silica column chro-
matography (final yield, 253 mg, 64%). The sodium salt of 3 was
obtained by stirring 3 in 100 mM NaOH in methanol, followed by
evaporation and redissolving in dH2O.
Preparation of Acyl Substrates
The acyl thioesters were prepared either by (1) combining the acyl
chloride directly with the free thiol in diethyl ether/triethylamine, or
(2) adding the free acid, diphenylphosphoryl azide, and the free thiol
in DMF/triethylamine. The following is an example of (1): benzoyl
chloride (370 ml, 3.2 mmol) was added slowly to a 20 ml solution of
HSNAC (288 ml, 3 mmol) and triethylamine (835 ml, 6 mmol) in diethyl
ether at 0C. The reaction was quenched with aqueous NH4Cl and
extracted twice with 80 ml ethyl acetate. The organic layer was dried
and evaporated to give a white solid (620 mg). The residue was pu-
rified with silica gel chromatography (EA:hexane, 20:80) to yield pure
benzoyl-SNAC (602 mg, 90% yield). 1H NMR: d 7.93 (d, 2H, 7.5 Hz),
7.57 (t, 1H, 7.5 Hz), 7.43 (m, 2H), 6.24 (br s, 1H), 3.50 (q, 2H, 6.3
Hz), 3.21 (t, 2H, 6.3 Hz), and 1.92 (s, 3H). 13C NMR: d 192.22,
170.51, 136.68, 133.71, 128.71, 128.58, 127.42, 127.29, 39.63,
28.56, and 23.22. The following is an example of (2): a-dimethylbuty-
ric acid (626 ml, 5 mmol) was dissolved in 25 ml DMF at 0C and
treated with diphenylphosphoryl azide (1.6 ml, 7.5 mmol) and trie-
thylamine (1.4 ml, 10 mmol) for 2 hr. HSNAC (535 ml, 5 mmol) was
added, and the solution was stirred for an additional 2 hr. The reac-
tion was quenched with the addition of 50 ml H2O and extracted
twice with ethyl acetate. The organic layer was dried, evaporated,
and a-dimethylbutyryl-SNAC was purified with silica gel chromatog-
raphy to give 750 mg of a colorless liquid (69% yield). 1H NMR: d 6.01
(br s, 1H), 3.38 (q, 2H, 6.3 Hz), 2.97 (t, 2H, 6.3 Hz), 1.93 (s, 3H), 1.58 (q,
2H, 7.5 Hz), 1.17 (s, 6H), and 0.81 (t, 3H, 7.5 Hz). 13C NMR: d 207.17,
170.20, 50.13, 39.79, 33.65, 27.88, 24.72, 23.13, and 8.9.
In Vitro Assay of LovD Activity
The assays were performed at room temperature in 50 mM HEPES
(pH 7.9), 50 mM NaCl, and 10 mM MgCl2. The acyl substrates and
3 were added, and the reaction was initiated with the addition of
LovD. To facilitate solubilization of hydrophobic acyl-SNAC and
acyl-SMTG substrates, DMSO was added to a final concentration
of 10%. Performing the in vitro assay at a slightly elevated tempera-
ture (30C) resulted in aggregation and precipitation of LovD. At
desired time points, 20 ml aliquots of the reaction mixture were ex-
tracted with ethyl acetate/1% acetic acid. The organic phase was
dried in a speedvac, redissolved in 20 ml acetonitrile, and analyzed
by HPLC. Similar procedures were followed to monitor the hydroly-
sis of lovastatin in the presence of LovD.
Preparation of 7
Commercially available sodium salt of 5 (4 mM) was added to a buff-
ered solution containing 50 mM HEPES (pH 7.9), 10 mM NaCl, and 10
mM MgCl2. LovD was added to a final concentration of 10 mM, and
the solution was incubated at room temperature for 10 hr. Complete
hydrolysis of 5 to 7 was determined by HPLC. After the level of 5
became undetectable, the reaction mixture was applied to a 10 kDa
MWCO spin column to remove the enzyme. The filtrate was collected
and used directly in subsequent assays.
Fermentation Conditions
Large-scale biosynthesis of 2 with BL21(DE3)/pAW31 was per-
formed in 500 ml LB media with 30 mg/l kanamycin. At an OD600 of
1.0, cells were concentrated to a final OD600 of 5.0 and induced
with 1 mM IPTG. Substrates 3 and acyl thioester were added to a final
concentration of 1 mM and 4 mM, respectively. At different time
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jected on to HPLC (20 ml). When maximum conversion was reached,
the broth was acidified to pH 2.0, extracted with ethyl acetate, dried,
and redissolved in toluene. The lactone forms of 3 and acylated
products were obtained by refluxing with a soxhlet apparatus.
Pure, acylated products were obtained after silica gel column chro-
matography.
NMR Characterization of Lovastatin Analogs
Substrate 4 (0.5 mg) was purified directly from a scaled-up in vitro
reaction. C8-benzoyl-monacolin J and 2 were purified from fermen-
tation broths. All data reported are for the lactonized compounds.
The diagnostic H8 and C8 signals in the following characterizations
are underlined.
4: 1H NMR: d 5.98 (d, 1H, 9.7 Hz, H-4), 5.78 (dd, 1H, 6.1 Hz, 9.5 Hz,
H-3), 5.53 (m, 1H, H-5), 5.39 (m, 1H, H-8), 4.64 (m, 1H, H-11), 4.37 (m,
1H, H-13), 2.80–2.61 (m, 2H, H-14), 2.45–2.40 (m, 1H, H-6), 2.40–2.30
(m, 1H, H-2), 2.31–2.26 (m, 2H, H-20), 2.30–2.20 (m, 1H, H-8a), 2.00–
1.91 (m, 1H, H-1), 1.96–1.93 (m, 2H, H-7), 1.90–1.80 (m, 1H, H-10),
1.70–1.60 (m, 2H, H-12), 1.70–1.60 (m, 2H, H-30), 1.49–1.32 (m, 2H,
H-9), 1.40–1.30 (m, 1H, C-10), 1.06 (d, 3H, 7.4 Hz, CH3-6), 0.88 (d,
3H, 7.1 Hz, CH3-2), and 0.83 (t, 3H, 7.4 Hz, H-4
0). 13C NMR:
d 174.32 (C-10), 171.45 (C-15), 133.21 (C-3), 131.62 (C-4a), 130.07
(C-5), 128.76 (C-4), 76.71 (C-11), 68.19 (C-8), 63.03 (C-13), 38.96 (C-
14), 37.85 (C-8a), 36.96 (C-12), 36.53 (C-1), 35.52 (C-20), 33.21 (C-7),
32.61 (C-10), 30.91 (C-2), 27.63 (C-6), 24.67 (C-9), 23.36 (CH3-6),
18.11 (C-30), 14.20 (CH3-2), and 11.67 (C-40).
C8-benzoyl-monacolin J: 1H NMR: d 8.03 (d, 2H, 7.5 Hz, C6H5-2),
7.56 (t, 1H, 7.5 Hz, C6H5-4), 7.44 (m, 2H, C6H5-3), 6.05 (d, 1H, 9.7
Hz, H-4), 5.82 (dd, 1H, 6.1 Hz, 9.6 Hz, H-3), 5.61 (br, 1H, H-5), 5.61
(m, 1H, H-8), 4.53 (m,1H, H-11), 4.21(m, 1H, H-13), 2.70–2.51 (m,
2H, H-14), 2.40–2.35 (m, 1H, H-6), 2.40–2.30 (m, 1H, H-2), 2.25–2.16
(m, 1H, H-8a), 2.03–1.97 (m, 1H, H-1), 1.99–1.93 (m, 2H, H-7), 1.90–
1.80 (m, 1H, H-10), 1.72–1.62 (m, 2H, H-12), 1.50–1.36 (m, 2H, H-9),
1.35–1.20 (m, 1H, C-10), 1.01 (d, 3H, 7.4 Hz, CH3-6), and 0.92 (d,
3H, 7.1 Hz, CH3-2).
13C NMR: d 170.18 (C-15), 166.27 (C-10), 133.26
(C-3), 133.08 (C6H5-4), 131.79 (C-4a), 130.50 (C6H5-1), 129.86 (C-5),
129.76 (C6H5-2), 128.59 (C6H5-3), 128.46 (C-4), 76.15 (C-11), 68.95
(C-8), 62.72 (C-13), 38.52 (C-14), 37.59 (C-8a), 37.12 (C-12), 36.05
(C-1), 32.83 (C-7), 32.63 (C-10), 30.95 (C-2), 27.56 (C-6), 24.17 (C-9),
22.73 (CH3-6), and 14.07 (CH3-2).
2: 1H NMR: d 5.98 (d, 1H, 9.6 Hz, H-4), 5.77 (dd, 1H, 6.1 Hz, 9.6 Hz,
H-3), 5.50 (m, 1H, H-5), 5.36 (m, 1H, H-8), 4.61 (m, 1H, H-11), 4.37 (m,
1H, H-13), 2.80–2.60 (m, 2H, H-14), 2.45–2.40 (m, 1H, H-6), 2.40–2.30
(m, 1H, H-2), 2.30–2.20 (m, 1H, H-8a), 2.00–1.91 (m, 1H, H-1), 1.96–
1.93 (m, 2H, H-7), 1.90–1.80 (m, 1H, H-10), 1.70–1.60 (m, 2H, H-12),
1.60–1.50 (q, 2H, 7.4 Hz, H-30), 1.49–1.32 (m, 2H, H-9), 1.40–1.30
(m, 1H, C-10), 1.12 (d, 6H, 3.0 Hz, CH3-2
0), 1.08 (d, 3H, 7.4 Hz, CH3-
6), 0.88 (d, 3H, 7.1 Hz, CH3-2), and 0.83 (t, 3H, 7.4 Hz, H-4
0). 13C
NMR: d 178.29 (C-10), 170.66 (C-15), 133.22 (C-3), 131.84 (C-4a),
130.05 (C-5), 128.72 (C-4), 76.69 (C-11), 68.36 (C-8), 63.00 (C-13),
43.36 (C-20), 38.94 (C-14), 37.86 (C-8a), 36.96 (C-12), 36.53 (C-1),
33.34 (C-30), 33.24 (C-7), 32.60 (C-10), 30.98 (C-2), 27.61 (C-6),
25.13 (CH3-2
0), 25.10 (CH3-20), 24.65 (C-9), 23.39 (CH3-6), 14.22
(CH3-2), and 9.67 (C-4
0).
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